financetom
Business
financetom
/
Business
/
Tesla Stock Trades Lower Premarket: What's Weighing Down On EV Giant Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tesla Stock Trades Lower Premarket: What's Weighing Down On EV Giant Today
Mar 19, 2024 5:36 AM

Tesla, Inc. ( TSLA ) shares fell in premarket trading on Tuesday after rallying over 6% in the previous session.

Tech optimism, bargain-hunting and the scepter of vehicle price hikes supported the stock on Monday after it dipped to a 10-month low of $160.51 (intraday) last Thursday.

Sentiment appears to have reversed course, as the stock is left to contend with a few negative catalysts. Data released from China showed that weekly insurance registrations for Tesla electric vehicles fell 6.8% week-over-week to 12,300 units in the week ended March 17, CnEVPost reported. So far this month, Tesla sold 31,000 units, going by the insurance registrations data.

China is a key market for Tesla and softness in the country does not bode well for the EV giant as it prepares to report its first-quarter deliveries in about two weeks. Analysts fear sales will fall short of the consensus expectations and have been reducing their estimates.

Tesla shares could also take a hit from the broader market weakness, with the futures trading pointing to a negative open on Tuesday. The Federal Reserve led by Jerome Powell is widely expected to keep rates unchanged on Wednesday but traders will sift through the post-meeting policy statement, the dot-plot curve and Powell’s testimony to get a sense of where rates are headed in the near-term. As such, the Fed rates stand at a 22-year high of 5.25%-5.50%.

A higher interest-rate environment is negative for growth stocks such as Tesla.

In premarket, Tesla fell 1.04% at $172, according to Benzinga Pro data.

See Also: Everything You Need To Know About Tesla Stock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Frontier Group Holdings Insider Sold Shares Worth $2,342,753, According to a Recent SEC Filing
Frontier Group Holdings Insider Sold Shares Worth $2,342,753, According to a Recent SEC Filing
Mar 7, 2024
07:30 AM EST, 03/07/2024 (MT Newswires) -- Barry Biffle, Director, CEO, around March 04, 2024, sold 308,774 shares in Frontier Group Holdings ( ULCC ) for $2,342,753. Following the Form 4 filing with the SEC, Biffle has control over a total of 821,930 shares of the company, with 772,981 shares held directly and 48,949 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1670076/000156218024002385/xslF345X03/primarydocument.xml...
NYCB total deposits drop 7% to $77.2 billion, shares fall
NYCB total deposits drop 7% to $77.2 billion, shares fall
Mar 7, 2024
(Reuters) - New York Community Bancorp ( NYCB ) disclosed on Thursday it held deposits of $77.2 billion, down roughly 7% from the $83 billion it had on Feb. 5, sending its shares down 3.3% before the bell. The lender also said its strategic initiatives for the year include lowering its commercial real estate exposure. NYCB on Wednesday said it...
Boehringer to cap out-of-pocket inhaler cost at $35 per month
Boehringer to cap out-of-pocket inhaler cost at $35 per month
Mar 7, 2024
March 7 (Reuters) - Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German drugmaker said on Thursday. The company said its new program will dramatically decrease costs at the pharmacy counter for patients, including those who are uninsured or underinsured. High healthcare...
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell
Mar 7, 2024
07:33 AM EST, 03/07/2024 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) reported a Q4 net loss of $0.33 per diluted share, narrower than its loss of $1.16 a year earlier. Analysts polled by Capital IQ expected a loss of $0.49 per share. Revenue for the quarter ended Dec. 31 was $14 million, up from $10.5 million a year earlier....
Copyright 2023-2026 - www.financetom.com All Rights Reserved